Well Referenced

Tag: FEV1

Effect of Mesenchymal Stromal Cell Infusions on Lung Function in COPD Patients with High CRP Levels

This post-hoc analysis of a Phase 1/2 randomized, placebo-controlled trial evaluated the efficacy of systemic administration of bone marrow-derived allogeneic mesenchymal stromal cells (remestemcel-L) in COPD patients stratified by baseline C-reactive protein (CRP) levels. In patients with CRP ≥ 4 mg/L, remestemcel-L treatment led to significant improvements in forced expiratory

Read More »
June 26, 2025 No Comments

Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial

This Phase II randomized, double-blind, placebo-controlled trial assessed the safety and efficacy of intravenous allogeneic human mesenchymal stem cells (allo-hMSCs) in 30 elderly patients (mean age 75.5 years) with aging frailty. Participants received either 100 million or 200 million allo-hMSCs or placebo. No treatment-related serious adverse events were observed. The

Read More »
June 26, 2025 No Comments

Nebulized glutathione induces bronchoconstriction in patients with mild asthma

This randomized, double-blind, placebo-controlled crossover study evaluated the effects of nebulized glutathione (GSH) on airway responsiveness in eight patients with mild asthma. While GSH is known for its antioxidant properties, nebulized administration (600 mg in saline) caused significant bronchoconstriction, with a 19% drop in FEV1 and a 61% increase in

Read More »
June 26, 2025 No Comments